The management of lung cancer necessitates a multi-disciplinary approach to maximize the options for scientifically validated cancer care delivery.
Campbell, CA (PRWEB) February 03, 2015
The Radiosurgery Society (RSS), a non-profit medical society, announced today a study from the RSSearch® Patient Registry describing the treatment management practices and clinical outcomes of stereotactic body radiotherapy (SBRT) for the treatment of early-stage non-small cell lung cancer (NSCLC). The study published in the January, 2015, issue of the Journal of Radiation Oncology Open Access (http://link.springer.com/article/10.1007/s13566-014-0177-0), included 723 patients with early-stage NSCLC treated with SBRT at 14 radiotherapy centers across the United States. SBRT is a type of radiation treatment that delivers high doses of radiation in a short number of treatment sessions. This is one of the largest studies to date to report on SBRT for the treatment of NSCLC from a multi-center patient registry and illuminates the practices and outcomes in a real world setting.
The study included 509 patients with T1 NSCLC and 214 patients with T2 NSCLC treated with SBRT. SBRT resulted in tumor control rates and overall survival rates comparable to previously reported studies of NSCLC patients treated with surgery. In addition, patients with larger tumors (T2 lesions) benefited when treated with higher SBRT doses. The study reinforces the benefits of SBRT for the treatment of early-stage NSCLC in medically inoperable patients.
“This large real world data is truly valuable in the discussion of SBRT for early-stage lung cancer, as it espouses community practice outside rigidly controlled randomized trials,” said corresponding senior author Anand Mahadevan, M.D., Assistant Professor, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Mass.
“The management of lung cancer necessitates a multi-disciplinary approach to maximize the options for scientifically validated cancer care delivery. This article represents one of the largest multi-center database series validating the effectiveness of SBRT as a curative form of treating early stage NSCLC in medically and technically inoperable lung cancer patients,” said study co-author Paul Chomiak, M.D., Chief of Thoracic Surgical Oncology, Sacred Heart Cancer Center, Pensacola, Fla. “Through my direct collaboration with radiation oncologists, I am able to actively participate in the treatment process for my lung cancer patients that may not be candidates for a conventional thoracic surgical resection. I would urge all thoracic surgeons to become actively involved in SBRT technology.”
The field of radiosurgery and SBRT is growing rapidly and tracking clinical outcomes in a patient registry will provide valuable information for the medical community and patients.
The RSSearch Patient Registry is an international patient registry dedicated to standardizing the collection of screening, treatment and outcomes data from patients with benign and cancerous tumors treated with stereotactic radiosurgery and/or SBRT. More than 40 centers around the world have participated in RSSearch with more than 15,000 enrolled patients. This is the largest database dedicated to SRS/SBRT patients and managed by a non-profit medical society.
About The Radiosurgery Society®
The Radiosurgery Society (RSS) – a non-profit, independent, multi-disciplinary organization of surgeons, radiation oncologists, physicists, and allied professionals, who are dedicated to advancing the science and clinical practice of radiosurgery. Originally formed in 2002 and becoming (501c6) in 2008, the Radiosurgery Society today represents approximately 500 members who perform stereotactic body radiotherapy and radiosurgery in hospitals and freestanding centers throughout the world.